source
- FDA orders label warnings for GLP-1 drugs over rare eye-loss riskThe U.S. Food and Drug Administration has issued a safety communication that requires all glucagon-like peptide-1 receptor agonist (GLP-1 RA) products to add new warnings to their labeling. The ad…
- Marea Therapeutics' triglyceride drug lowers levels without raising blood sugar in high-risk patientsMarea Therapeutics reported new data on its investigational lipid‑lowering medicine, showing it can further reduce triglyceride levels in patients with dangerously high blood concentrations. The s…Endpoints · 7h agoPositive readoutPositive